Elusys Therapeutics, Inc.

25 RIVERSIDE DR STE 1
PINE BROOK, NJ, 07058-9391  United States
(973) 808-0222
Company Type: Private Independent

Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. The company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim was approved by the US FDA in 2016 to treat and prevent inhaled anthrax; Elusys received federal funding for its research efforts on the drug. The company has partnered with Pfizer on another drug development program targeting S taphylococcus aureus (staph) infections, which have become increasingly prevalent and resistant to treatment. Elusys antibodies have potential applications in the treatment of additional infectious agents.

Try D&B Hoovers Free

Competitor Profiles

See detailed profiles for insights and prospects on this company's top competitors.

For Your Call

Essential information for a successful call

  •  EMPLOYEES 25
  •  SALES (MIL USD) 6.016145
  • Incorporated 1999
  • CREDIT PRESCREEN LOW RISK

Get full access to D&B Hoovers

With a Hoovers subscription you can get a comprehensive view of Elusys Therapeutics, Inc.

Start Live ChatChat

*Required Fields

FREE Alerts to Changes in Your D&B® Credit Scores!* Sign Up. Get CreditSignal® for FREE!*
Try D&B Credit FREE for 30 Days! Get Started. Try D&B Credit FREE for 30 Days